美国暂时免除印度药品制造商的新关税,以维持负担得起的药品供应。 US temporarily exempts Indian drugmakers from new tariffs to maintain affordable medicine supply.

美国暂时豁免印度制药公司25%的新关税,承认它们在向美国消费者提供负担得起的非专利药品方面的关键作用。 The US has temporarily exempted Indian pharmaceutical companies from new 25% tariffs, recognizing their crucial role in providing affordable generic medicines to American consumers. 目前印度商品的总关税为50%,但药房部门正在接受审查。 The total tariff on Indian goods now stands at 50%, but the pharma sector is under review. 印度的毒品制造者认为,美国消费者在任何增加的费用中首当其冲,因为他们严重依赖印度的基本药物供应。 Indian drug-makers argue that US consumers will bear the brunt of any increased costs, as they rely heavily on Indian supplies for essential medicines. 这一举动是美国谈判降低药物价格的更广泛战略的一部分,包括与主要制药公司讨论提高欧洲价格以降低美国成本。 The move is part of a broader US strategy to negotiate lower drug prices, including discussions with major pharmaceutical companies to increase prices in Europe to lower costs in the US.